Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
STAAR Surgical Company
STAA
NASDAQ·Healthcare·Medical - Instruments & Supplies·Mkt cap $1.4B
$27.79
▼ -1.28%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$15.59 - $35.87
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 60.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary Collamer material technology with biocompatible, UV-blocking properties
- Reversible vision correction solution differentiating ICL from permanent laser procedures
- Established global distribution network with direct sales presence in key markets
- Comprehensive product portfolio addressing multiple refractive errors with single platform
Bear Case
2 risks
- Average volatility.
- Extreme premium - high expectations embedded
Growth
Turning profitable
Rising global myopia prevalence, particularly in Asia-Pacific markets with high population density
Value
Extreme premium - high expectations embedded
Momentum
Hot
+39.3% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying STAA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 5, 2026
MAY 13, 2026
Reported EPS of $0.19 vs $0.03 consensus (+580.0% surprise). Revenue of $93.5M vs $78.7M expected (+18.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+580.0%
Next: May 5, 2026
Revenue trend · last 8Q
—
—
-36%
-45%
-55%
+7%
+18%
+120%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 26
Q1 26
$99.0M
$88.6M
$49.0M
$42.6M
$44.3M
$94.7M
$57.8M
$93.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
5.6%
Wall Street consensus
7 analysts · 43% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
43%
Hold
57%
Sell
0%
Median Price Target
$31.50
▲ +13.4% vs $27.79
Latest: Wedbush · May 29, 2026
5 analysts covering